Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
July 8, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
July 8, 2002
- Ain Pharmaciez: Sales Up 26.1% to \24.7 Bil.
July 8, 2002
- Korosho to Convert OPSR into Independent Administrative Agency in April 2004
July 8, 2002
- Tsuruha Acquires Potato Company of Yamagata
July 8, 2002
- Korosho Quickly Reviews NDA for Useful Drugs
July 8, 2002
- Discussions on Role of OTC Drugs Begin: Korosho
July 8, 2002
- ADRs Likely Caused by Glivec Reported: Korosho
July 8, 2002
- Pharmacists Ranked 5th in FY2002 Honesty/Ethics in Profession Poll
July 8, 2002
- Revised Bill of Health Insurance Law Approved by Lower House
July 8, 2002
- Iwaki Launches Mechanical Ventilators
July 8, 2002
- 1st-Class Products Invite 1st-Class People:Dr Aoki of Fujisawa
July 8, 2002
- REGULATORY NEWS IN BRIEF
July 8, 2002
- Korosho Compiles Report on Healthcare Devices
July 8, 2002
- BULLETIN
July 8, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 8, 2002
- PRESS SEMINAR
July 8, 2002
- Novartis Aims at \70 Bil. Sales of Diovan in 2004
July 8, 2002
- Candesartan Reduces Risk of Non-fatal Stroke in the Elderly
July 8, 2002
- Wako Pure Chemical Starts Contract DNA Sequencing Services
July 8, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…